Capricor Therapeutics Inc (CAPR) Upgraded to Hold by Zacks Investment Research

Zacks Investment Research upgraded shares of Capricor Therapeutics Inc (OTCMKTS:CAPR) from a sell rating to a hold rating in a report released on Friday.

According to Zacks, “Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California. “

CAPR has been the subject of several other research reports. HC Wainwright began coverage on shares of Capricor Therapeutics in a research note on Wednesday, July 6th. They set a buy rating and a $13.00 target price for the company. Roth Capital began coverage on shares of Capricor Therapeutics in a research report on Wednesday, June 15th. They issued a buy rating and a $12.00 price objective for the company.

Shares of Capricor Therapeutics (OTCMKTS:CAPR) opened at 3.2426 on Friday. Capricor Therapeutics has a 1-year low of $1.88 and a 1-year high of $5.40. The firm’s 50-day moving average price is $3.62 and its 200 day moving average price is $3.56. The stock’s market capitalization is $58.22 million.

Capricor Therapeutics (OTCMKTS:CAPR) last issued its quarterly earnings data on Monday, August 15th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by $0.02. Equities research analysts expect that Capricor Therapeutics will post ($1.04) earnings per share for the current fiscal year.

In other news, major shareholder Sinai Medical Center Cedars acquired 312,500 shares of Capricor Therapeutics stock in a transaction that occurred on Wednesday, September 21st. The stock was purchased at an average price of $3.20 per share, for a total transaction of $1,000,000.00. Following the completion of the transaction, the insider now directly owns 2,904,798 shares in the company, valued at $9,295,353.60. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

An institutional investor recently raised its position in Capricor Therapeutics stock. Vanguard Group Inc. increased its position in shares of Capricor Therapeutics Inc (OTCMKTS:CAPR) by 25.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 27,975 shares of the company’s stock after buying an additional 5,704 shares during the period. Vanguard Group Inc. owned 0.16% of Capricor Therapeutics worth $111,000 as of its most recent filing with the SEC.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications.

Get a free copy of the Zacks research report on Capricor Therapeutics (CAPR)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Capricor Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics Inc and related companies with's FREE daily email newsletter.

Leave a Reply

© 2006-2016 Mideast Time.